Free Trial

Summit Therapeutics Q2 2024 Earnings Report

Summit Therapeutics logo
$20.32 -0.28 (-1.36%)
As of 03/28/2025 04:00 PM Eastern

Summit Therapeutics EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.06
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Summit Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Summit Therapeutics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

Summit Therapeutics Earnings Headlines

Citigroup Upgrades Summit Therapeutics (BMV:SMMT)
[OPEN NOW] New rules to trade options with.
Here’s an update that could make your entire year. But first, a question. Could you get better wins if you applied a new set of rules to your trade? For example, when you meet your criteria to take a trade, could you improve your results by taking the same trade differently? From the audit I just did, it turns out the answer is a resounding YES! I applied a new set of rules to 100 live published trades from 2024. These 100 trades already got a whopping 69% win rate – taking a $10k model account risking 10% per trade to $63,304. But what happened when we applied these new rules? We got an 85.1% win rate and sent the same $10k account risking 10% per trade to over $200k!
Summit Therapeutics (NASDAQ:SMMT) Raised to "Buy" at Citigroup
See More Summit Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Summit Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Summit Therapeutics and other key companies, straight to your email.

About Summit Therapeutics

Summit Therapeutics (NASDAQ:SMMT), a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

View Summit Therapeutics Profile

More Earnings Resources from MarketBeat